Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALLO

Allogene Therapeutics Inc

Sep 15 • 04:00PM ET

1.15

+0.02 1.77 %

Healthcare • Biotechnology • USA • NASD

Peers: NTLA CRSP EDIT BEAM FDMT IOBT SGMO CLLS DTIL CYTK

| Held by: VTI IWM VXF IWN IBB VTWO SCHA VHT MOON DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.11	Insider Own	31.06%	Shs Outstand	220.13M	Perf Week	0.88%
Market Cap	255.16M	Forward P/E	-	EPS next Y	-0.89	Insider Trans	-0.14%	Shs Float	152.97M	Perf Month	7.48%
Enterprise Value	69.04M	PEG	-	EPS next Q	-0.22	Inst Own	60.67%	Short Float	13.04%	Perf Quarter	-14.18%
Income	-236.91M	P/S	-	EPS this Y	27.77%	Inst Trans	-6.53%	Short Ratio	5.05	Perf Half Y	-40.72%
Sales	0.00M	P/B	0.73	EPS next Y	6.90%	ROA	-42.40%	Short Interest	19.94M	Perf YTD	-46.01%
Book/sh	1.57	P/C	0.93	EPS next 5Y	11.75%	ROE	-55.12%	52W High	3.78 -69.58%	Perf Year	-60.48%
Cash/sh	1.23	P/FCF	-	EPS past 3/5Y	0.45% 6.26%	ROIC	-55.90%	52W Low	0.86 33.40%	Perf 3Y	-92.53%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-94.22% -	Gross Margin	-	Volatility	4.63% 6.74%	Perf 5Y	-96.52%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	30.91%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.92	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	50.53	Recom	1.54
Dividend Gr. 3/5Y	- -	Current Ratio	8.92	EPS Q/Q	33.36%	SMA20	1.59%	Beta	0.41	Target Price	7.51
Payout	-	Debt/Eq	0.25	Sales Q/Q	-	SMA50	-3.39%	Rel Volume	0.52	Prev Close	1.13
Employees	229	LT Debt/Eq	0.23	Earnings	Aug 13 AMC	SMA200	-26.45%	Avg Volume	3.95M	Price	1.15
IPO	Oct 11, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.08% -	Trades		Volume	2,062,241	Change	1.77%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Mar-14-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$5
Aug-08-24	Resumed	Oppenheimer	Outperform	$13 → $11
May-31-24	Initiated	Piper Sandler	Overweight	$11
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Dec-08-23	Initiated	Citigroup	Buy	$7
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform	$28
Mar-21-23	Initiated	Bernstein	Mkt Perform	$6
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight	$20 → $11
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform	$12
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform	$24 → $9
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy	$9 → $32
Jun-03-22	Initiated	Robert W. Baird	Neutral	$11
Feb-28-22	Reiterated	B. Riley Securities	Buy	$30 → $21
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Stifel	Buy → Hold	$44 → $18
Oct-08-21	Downgrade	Goldman	Buy → Neutral	$71 → $20

Show Previous Ratings

Sep-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? (Zacks)
Sep-08-25 09:42AM	Investing in Oncology: 3 Cancer Stocks With Promising Pipelines (Zacks)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks)
10:04AM	AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia (Zacks)
Aug-27-25 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conference (GlobeNewswire)
11:11AM	Loading…
Aug-14-25 11:11AM	Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
03:15AM	Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
Aug-13-25 04:12PM	Allogene Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Aug-12-25 09:34AM	Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-06-25 08:30AM	Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update (GlobeNewswire) -5.36%
Aug-01-25 08:30AM	Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma (GlobeNewswire) -12.20%
07:10AM	Regeneron cancer bispecific rejected again; Allogene discloses trial death (BioPharma Dive)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire) +16.90%
Jul-21-25 09:41AM	Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025 (Zacks) +5.60%
11:30AM	Loading…
Jun-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? (Zacks)
Jun-04-25 12:00PM	All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy (Zacks)
Jun-01-25 10:45AM	Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO (GlobeNewswire)
May-23-25 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-22-25 05:17PM	Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel (GlobeNewswire)
May-20-25 09:11AM	REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research (Zacks) +6.42%
May-16-25 06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive)
May-15-25 11:04AM	Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +14.40%
09:43AM	Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays (GuruFocus.com)
09:35AM	Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks) -15.68%
10:46AM	Q1 2025 Allogene Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
06:29AM	Allogene's Q1 Earnings In Line With Estimates, Sales Nil (Zacks)
03:18AM	Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
04:11PM	Loading…
May-13-25 04:11PM	Allogene Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:42AM	Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
May-12-25 09:40AM	Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
09:20AM	RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up (Zacks)
May-09-25 08:26AM	Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-06-25 08:30AM	Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update (GlobeNewswire) -20.99%
Apr-23-25 10:12AM	Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-08-25 06:46AM	FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug (Zacks)
Apr-07-25 08:30AM	Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma (GlobeNewswire)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-14-25 03:00PM	Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... (GuruFocus.com)
Mar-13-25 04:11PM	Allogene Therapeutics: Q4 Earnings Snapshot (Associated Press Finance) -8.25%
04:02PM	Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Mar-03-25 08:30AM	Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update (GlobeNewswire) -7.69%
Feb-26-25 08:30AM	Allogene Therapeutics Announces Participation in March Investor Conference (GlobeNewswire)
Feb-25-25 04:10PM	Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia (GlobeNewswire) -7.24%
Feb-13-25 04:30PM	Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology (GlobeNewswire) +44.68%
Feb-04-25 08:30AM	Allogene Therapeutics Announces Participation in February Investor Conferences (GlobeNewswire)
Jan-29-25 08:30AM	Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer (GlobeNewswire)
Jan-28-25 08:30AM	Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases (GlobeNewswire)
Dec-26-24 12:00PM	Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire)
Dec-16-24 08:30AM	Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.99%
Dec-12-24 08:30AM	Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman (GlobeNewswire) -5.61%
Nov-25-24 12:00PM	Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why (Zacks)
Nov-19-24 08:30AM	Allogene Therapeutics Announces Participation in December Investor Conferences (GlobeNewswire)
Nov-18-24 08:30AM	Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence (GlobeNewswire) -5.29%
Nov-08-24 06:07AM	Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... (GuruFocus.com)
Nov-07-24 04:11PM	Allogene Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
10:00AM	Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS (GlobeNewswire)
Nov-06-24 07:31AM	Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +7.69%
Nov-05-24 09:10AM	Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-04-24 08:30AM	Allogene Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire) +10.29%
Oct-31-24 10:01AM	Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-30-24 08:30AM	Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update (GlobeNewswire) -5.71%
Oct-29-24 08:30AM	Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) (GlobeNewswire)
Oct-22-24 04:05PM	Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors (GlobeNewswire)
Oct-03-24 07:19AM	Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now (Insider Monkey)
Sep-30-24 08:30AM	Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference (GlobeNewswire)
Sep-26-24 08:30AM	Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence (GlobeNewswire)
Sep-14-24 05:39PM	Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-06-24 11:31AM	Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-08-24 09:50AM	Allogene (ALLO) Posts Narrower Than Expected Loss in Q2 (Zacks)
08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
06:00AM	7 Biotech Stocks to Buy for Their Game-Changing Potential (InvestorPlace)
Aug-07-24 04:10PM	Allogene Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Jul-31-24 08:30AM	Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update (GlobeNewswire)
Jul-01-24 08:30AM	Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL) (GlobeNewswire)
Jun-27-24 10:13AM	Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-20-24 08:30AM	Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse (GlobeNewswire) +9.42%
Jun-12-24 11:30AM	Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound? (Zacks)
May-29-24 08:55AM	Insiders Pour Millions Into These 2 Strong Buy Stocks (TipRanks)
May-28-24 04:05PM	If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names (InvestorPlace)
May-23-24 08:30AM	Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire)
May-21-24 01:56PM	Hedge Fund and Insider Trading News: Ken Griffin, Sanjay Shah, David Tepper, Stanley Druckenmiller, Michael Burry, Cevian Capital, Elliott Management, Millennium Management, Eisler Capital, Allogene Therapeutics Inc (ALLO), Carvana Co. (CVNA) and More (Insider Monkey)
08:16AM	Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating (MT Newswires)
May-16-24 08:13AM	HC Wainwright Adjusts Price Target on Allogene Therapeutics to $9 From $10, Keeps Buy Rating (MT Newswires)
May-14-24 12:56PM	Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag (Zacks)
09:14AM	Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating (MT Newswires)
08:21AM	B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating (MT Newswires)
03:06AM	Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 08:55PM	ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.07%
05:36PM	Allogene Therapeutics Prices $110 Million Offering (MT Newswires)
05:10PM	Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:47PM	Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock (GlobeNewswire)

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MESSEMER DEBORAH M.	Director	Jun 10 '25	Sale	1.42	36,885	52,377	107,431	Jun 12 04:18 PM
MESSEMER DEBORAH M.	Director	Jun 10 '25	Proposed Sale	1.42	36,885	52,391		Jun 10 04:29 PM
Yoshiyama Annie	SVP, Finance	Apr 21 '25	Sale	1.41	9,601	13,537	130,663	Apr 23 05:28 PM
Yoshiyama Annie	Officer	Apr 21 '25	Proposed Sale	1.41	9,601	13,537		Apr 21 04:49 PM
Chang David D	President and CEO	Mar 14 '25	Sale	1.96	46,668	91,469	5,276,569	Mar 18 05:30 PM
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Mar 14 '25	Sale	1.98	5,488	10,839	218,507	Mar 18 05:28 PM
Beneski Benjamin Machinas	Officer	Mar 14 '25	Proposed Sale	1.97	5,488	10,839		Mar 14 04:58 PM
Chang David D	Officer	Mar 14 '25	Proposed Sale	1.96	46,668	91,469		Mar 14 04:57 PM
MESSEMER DEBORAH M.	Director	Feb 18 '25	Sale	2.43	13,313	32,351	144,316	Feb 20 04:15 PM
MESSEMER DEBORAH M.	Director	Feb 18 '25	Proposed Sale	2.43	13,313	32,329		Feb 18 05:27 PM
Douglas Earl Martin	SVP, General Counsel	Feb 03 '25	Sale	1.71	6,404	10,951	587,848	Feb 05 04:16 PM
Parker Geoffrey M.	CHIEF FINANCIAL OFFICER	Feb 03 '25	Sale	1.73	4,361	7,545	1,301,540	Feb 05 04:15 PM
MOORE TIMOTHY L.	Chief Technical Officer	Feb 03 '25	Sale	1.71	14,746	25,216	250,713	Feb 05 04:14 PM
Chang David D	President and CEO	Feb 03 '25	Sale	1.68	46,003	77,285	5,317,237	Feb 05 04:13 PM
Roberts Zachary	EVP of R&D	Feb 03 '25	Sale	1.70	18,832	32,014	643,135	Feb 05 04:12 PM
Roberts Zachary	Officer	Feb 03 '25	Proposed Sale	1.70	18,832	32,014		Feb 03 04:32 PM
Chang David D	Officer	Feb 03 '25	Proposed Sale	1.68	46,003	77,446		Feb 03 04:31 PM
Douglas Earl Martin	Officer	Feb 03 '25	Proposed Sale	1.71	6,404	10,951		Feb 03 04:30 PM
MOORE TIMOTHY L.	Officer	Feb 03 '25	Proposed Sale	1.71	14,746	25,225		Feb 03 04:29 PM
Parker Geoffrey M.	Officer	Feb 03 '25	Proposed Sale	1.73	4,361	7,545		Feb 03 04:28 PM
Roberts Zachary	EVP of R&D	Jan 21 '25	Sale	1.78	27,199	48,414	488,054	Jan 23 04:30 PM
Roberts Zachary	Officer	Jan 21 '25	Proposed Sale	1.78	27,199	48,499		Jan 21 04:22 PM
MESSEMER DEBORAH M.	Director	Dec 09 '24	Sale	2.18	9,136	19,916	157,629	Dec 10 04:53 PM
Humer Franz B	Director	Dec 05 '24	Sale	2.16	9,221	19,917	307,507	Dec 09 04:05 PM
MESSEMER DEBORAH M.	Director	Dec 09 '24	Proposed Sale	2.18	9,136	19,954		Dec 09 04:02 PM
Humer Franz B	Director	Dec 03 '24	Proposed Sale	2.48	9,221	22,868		Dec 02 02:11 PM
Parker Geoffrey M.	Officer	Oct 21 '24	Proposed Sale	2.84	36,404	103,501		Oct 21 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALLO

Allogene Therapeutics Inc

Upgrade your FINVIZ experience